Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Core Insights - Jyong Biotech Ltd. announced updated statistical analyses from its Phase II clinical trial of MCS-8, highlighting its potential in treating urinary system diseases and possibly expanding to lipid management and cardiovascular diseases [1][3]. Clinical Trial Results - The Phase II clinical trial showed a 27.3% reduction in overall prostate cancer incidence and a 17.1% reduction in high-grade prostate cancer incidence compared to placebo [3]. - Long-term administration of MCS-8 for two years did not increase adverse events, with no serious adverse events or negative effects on liver, kidney function, or blood pressure observed [3]. Metabolic Indicators - MCS-8 demonstrated improved lipid control, with a statistically significant reduction in total cholesterol levels (P = 0.036) and no increase in serum lactate dehydrogenase (LDH) levels in the MCS-8 group, suggesting no cellular damage [2][7]. Development and Technology - MCS-8 is developed using Jyong Biotech's patented pharmaceutical composition technology, which enhances bioavailability and physiological efficacy, allowing for multiple dosage forms and indications [4]. Company Overview - Jyong Biotech Ltd. is a biotechnology company focused on developing innovative plant-derived drugs for urinary system diseases, with a commitment to research and development since its inception in 2002 [6].